Trial Profile

A phase 1/2 study of GH001 in patients with treatment-resistant depression

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 5 Methoxy N N Dimethyltryptamine (Primary)
Indications Major depressive disorder
Focus Adverse reactions; Therapeutic Use
Sponsors GH Research

Most Recent Events

18 Oct 2022 Results of a Phase 1/2 trial (GH001-TRD-102) presented at the 35th Annual Congress of the European College of Neuropsychopharmacology
18 May 2022 According to a GH Research media release, data from this study will be presented at the American Society of Clinical Psychopharmacology 2022 Annual Meeting.
06 Dec 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com